Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
8 hedge funds and large institutions have $2.54M invested in Altamira Therapeutics Ltd in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
0% more funds holding
Funds holding: 8 → 8 (0)
65% less capital invested
Capital invested by funds: $7.2M → $2.54M (-$4.66M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.15M |
| 2 |
Morgan Stanley
New York
|
+$187K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$80.3K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$80.3K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$53.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$457K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$33K |
| 3 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$32K |
| 4 |
Bank of New York Mellon
New York
|
-$9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SI
1
Sofinnova Investments
Menlo Park,
California
| $1.25M | +$2.62M | +98 | New |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $549K | +$1.15M | +43 | New |
|
|
BG
3
Bellevue Group
Kuesnacht,
Switzerland
| $347K | – | – | – |
|
|
4
Morgan Stanley
New York
| $243K | +$187K | +7 | +58% |
|
|
5
Citadel Advisors
Miami,
Florida
| $45K | +$80.3K | +3 | New |
|
|
VF
6
Virtu Financial
New York
| $35K | – | – | – |
|
|
WS
7
Wedbush Securities
Los Angeles,
California
| $33K | +$53.6K | +2 | +200% |
|
|
TSS
8
Two Sigma Securities
New York
| $33K | +$80.3K | +3 | New |
|
9
UBS Group
Zurich,
Switzerland
| $2K | – | – | – |
|
|
TCM
10
Tekla Capital Management
Boston,
Massachusetts
| – | -$457K | -10 | Closed |
|
|
SPC
11
Sigma Planning Corp
Ann Arbor,
Michigan
| – | -$32K | -1 | Closed |
|
|
12
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$33K | -1 | Closed |
|
|
13
Bank of New York Mellon
New York
| – | -$9K | – | – |
|
|
BTS
14
BB&T Securities
Richmond,
Virginia
| – | -$6K | – | – |
|
|
15
Geode Capital Management
Boston,
Massachusetts
| – | -$7K | – | – |
|
CYTO Hedge Fund Activity: Q1 2018 in Review
8 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q1 2018, worth a combined $2.54M — down 65% from $7.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CYTO positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.15M. The largest seller was Tekla Capital Management, exiting entirely with an estimated $457K sold.
- 8 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $2.54M of Altamira Therapeutics Ltd stock for Q1 2018, down 65% quarter-over-quarter.
- 4 funds opened new Altamira Therapeutics Ltd positions in Q1 2018 and 3 closed out, a net change of +1 holder.
- The largest Altamira Therapeutics Ltd buyer in Q1 2018 was Sabby Management, an estimated $1.15M added.
- The largest Altamira Therapeutics Ltd seller in Q1 2018 was Tekla Capital Management, an estimated $457K sold.
Based on aggregated 13F filings for Q1 2018.